Publications by authors named "Nadia Rubis"

Claim this Profile
R
Randomized Trial of Dapagliflozin in Patients With Nondiabetic Stage 4 CKD.
Matias Trillini, Alessandro Villa, Annalisa Perna, Tobia Peracchi, Diego Fidone, Nadia Rubis

Kidney Int Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.
Manuel Alfredo Podestà, Matias Trillini, Valentina Portalupi, Alessia Gennarini, Federica Tomatis, Nadia Rubis

Am J Kidney Dis· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM).
Norberto Perico, Giuseppe Remuzzi, Matthew D Griffin, Paul Cockwell, Alexander P Maxwell, Nadia Rubis

J Am Soc Nephrol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A GWAS in the pandemic epicenter highlights the severe COVID-19 risk locus introgressed by Neanderthals.
Matteo Breno, Marina Noris, Nadia Rubis, Aneliya Ilieva Parvanova, Davide Martinetti

iScience· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome.
Marina Vivarelli, Manuela Colucci, Mattia Algeri, Federica Zotta, Francesco Emma, Nadia Rubis

JCI Insight· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial.
Matias Trillini, Anna Caroli, Norberto Perico, Andrea Remuzzi, Paolo Brambilla, Nadia Rubis

Clin J Am Soc Nephrol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2).
Elena Consolaro, Fredy Suter, Nadia Rubis, Stefania Pedroni, Chiara Moroni

Front Med (Lausanne)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial).
Piero Ruggenenti, Monica Cortinovis, Matias Trillini, Aneliya Parvanova, Manuela Abbate, Nadia Rubis

Diabetes Res Clin Pract· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19.
Sistiana Aiello, Sara Gastoldi, Miriam Galbusera, Piero Ruggenenti, Valentina Portalupi, Nadia Rubis

Blood Adv· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study.
Fredy Suter, Elena Consolaro, Stefania Pedroni, Chiara Moroni, Elena Pastò, Nadia Rubis

EClinicalMedicine· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study.
Piero Ruggenenti, Monica Cortinovis, Aneliya Parvanova, Matias Trillini, Ilian P Iliev, Nadia Rubis

PLoS Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis: The ARCADIA Multicenter Randomized Controlled Trial.
Piero Ruggenenti, Manuel Alfredo Podestà, Matias Trillini, Annalisa Perna, Tobia Peracchi, Nadia Rubis

Clin J Am Soc Nephrol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
Piero Ruggenenti, Erica Daina, Alessia Gennarini, Camillo Carrara, Sara Gamba, Nadia Rubis

Am J Kidney Dis· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.
Norberto Perico, Piero Ruggenenti, Annalisa Perna, Anna Caroli, Matias Trillini, Nadia Rubis

PLoS Med· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial.
Aneliya Parvanova, Matias Trillini, Manuel A Podestà, Ilian P Iliev, Carolina Aparicio, Nadia Rubis

J Endocr Soc· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.
Aneliya Parvanova, Matias Trillini, Manuel A Podestà, Ilian Petrov Iliev, Barbara Ruggiero, Nadia Rubis

Lancet Diabetes Endocrinol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.
Antonio Pisani, Massimo Sabbatini, Massimo Imbriaco, Eleonora Riccio, Nadia Rubis

Clin Gastroenterol Hepatol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.
Piero Ruggenenti, Giorgio Gentile, Norberto Perico, Annalisa Perna, Luca Barcella, Nadia Rubis

Clin J Am Soc Nephrol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.
Piero Ruggenenti, Barbara Ruggiero, Paolo Cravedi, Marina Vivarelli, Laura Massella, Nadia Rubis

J Am Soc Nephrol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.
Anna Caroli, Norberto Perico, Annalisa Perna, Luca Antiga, Paolo Brambilla, Nadia Rubis

Lancet· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes.
Piero Ruggenenti, Esteban Porrini, Nicola Motterlini, Annalisa Perna, Aneliya Parvanova Ilieva, Nadia Rubis

J Am Soc Nephrol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial.
Piero Ruggenenti, Giuseppe Lauria, Ilian Petrov Iliev, Anna Fassi, Aneliya Parvanova Ilieva, Nadia Rubis

Hypertension· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.
Piero Ruggenenti, Anna Fassi, Aneliya Parvanova Ilieva, Ilian Petrov Iliev, Carlos Chiurchiu, Nadia Rubis

J Hypertens· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
Piero Ruggenenti, Annalisa Perna, Marcello Tonelli, Giacomina Loriga, Nicola Motterlini, Nadia Rubis

Clin J Am Soc Nephrol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sirolimus therapy to halt the progression of ADPKD.
Norberto Perico, Luca Antiga, Anna Caroli, Piero Ruggenenti, Giorgio Fasolini, Nadia Rubis

J Am Soc Nephrol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis